Identifying pregnancy episodes and estimating the last menstrual period using an administrative database in Korea: an application to patients with systemic lupus erythematosus
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES: This study developed an algorithm for identifying pregnancy episodes and estimating the last menstrual period (LMP) in an administrative claims database and applied it to investigate the use of pregnancy-incompatible immunosuppressants among pregnant women with systemic lupus erythematosus (SLE). METHODS: An algorithm was developed and applied to a nationwide claims database in Korea. Pregnancy episodes were identified using a hierarchy of pregnancy outcomes and clinically plausible periods for subsequent episodes. The LMP was estimated using preterm delivery, sonography, and abortion procedure codes. Otherwise, outcome-specific estimates were applied, assigning a fixed gestational age to the corresponding pregnancy outcome. The algorithm was used to examine the prevalence of pregnancies and utilization of pregnancy-incompatible immunosuppressants (cyclophosphamide [CYC]/mycophenolate mofetil [MMF]/methotrexate [MTX]) and non-steroidal anti-inflammatory drugs (NSAIDs) during pregnancy in SLE patients. RESULTS: The pregnancy outcomes identified in SLE patients included live births (67%), stillbirths (2%), and abortions (31%). The LMP was mostly estimated with outcome-specific estimates for full-term births (92.3%) and using sonography procedure codes (54.7%) and preterm delivery diagnosis codes (37.9%) for preterm births. The use of CYC/MMF/MTX decreased from 7.6% during preconception to 0.2% at the end of pregnancy. CYC/MMF/MTX use was observed in 3.6% of women within 3 months preconception and 2.5% during 0-7 weeks of pregnancy. CONCLUSIONS: This study presents the first pregnancy algorithm using a Korean administrative claims database. Although further validation is necessary, this study provides a foundation for evaluating the safety of medications during pregnancy using secondary databases in Korea, especially for rare diseases.
Abstract
OBJECTIVES: This study developed an algorithm for identifying pregnancy episodes and estimating the last menstrual period (LMP) in an administrative claims database and applied it to investigate the use of pregnancy-incompatible immunosuppressants among pregnant women with systemic lupus erythematosus (SLE). METHODS: An algorithm was developed and applied to a nationwide claims database in Korea. Pregnancy episodes were identified using a hierarchy of pregnancy outcomes and clinically plausible periods for subsequent episodes. The LMP was estimated using preterm delivery, sonography, and abortion procedure codes. Otherwise, outcome-specific estimates were applied, assigning a fixed gestational age to the corresponding pregnancy outcome. The algorithm was used to examine the prevalence of pregnancies and utilization of pregnancy-incompatible immunosuppressants (cyclophosphamide [CYC]/mycophenolate mofetil [MMF]/methotrexate [MTX]) and non-steroidal anti-inflammatory drugs (NSAIDs) during pregnancy in SLE patients. RESULTS: The pregnancy outcomes identified in SLE patients included live births (67%), stillbirths (2%), and abortions (31%). The LMP was mostly estimated with outcome-specific estimates for full-term births (92.3%) and using sonography procedure codes (54.7%) and preterm delivery diagnosis codes (37.9%) for preterm births. The use of CYC/MMF/MTX decreased from 7.6% during preconception to 0.2% at the end of pregnancy. CYC/MMF/MTX use was observed in 3.6% of women within 3 months preconception and 2.5% during 0-7 weeks of pregnancy. CONCLUSIONS: This study presents the first pregnancy algorithm using a Korean administrative claims database. Although further validation is necessary, this study provides a foundation for evaluating the safety of medications during pregnancy using secondary databases in Korea, especially for rare diseases.
참고문헌 (34)
- Andrade SE, "Administrative claims data versus augmented pregnancy data for the study of pharmaceutical treatments in pregnancy", Curr Epidemiol Rep, 4, pp.106~116 (2017)[DOI]
- "ENCePP guide on methodological standards in pharmacoepidemiology standards and guidance"[URL]
- MacDonald SC, "Identifying pregnancies in insurance claims data : methods and application to retinoid teratogenic surveillance", Pharmacoepidemiol Drug Saf, 28, pp.1211~1221 (2019)[DOI]
- Matcho A, "Inferring pregnancy episodes and outcomes within a network of observational databases", PLoS One, 13, pp.e0192033~ (2018)[DOI]
- Sarayani A, "Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies", Am J Obstet Gynecol, 227, pp.263~ (2022)[DOI]
- Moll K, "Validating claims-based algorithms determining pregnancy outcomes and gestational age using a linked claims-electronic medical record database", Drug Saf, 44, pp.1151~1164 (2021)[DOI]
- Blotière PO, "Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases : an application to antiepileptic drug use in 4. 9 million pregnant women in France", Pharmacoepidemiol Drug Saf, 27, pp.763~770 (2018)[DOI]
- Wentzell N, "Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data", Pharmacoepidemiol Drug Saf, 27, pp.1005~1010 (2018)[DOI]
- Naleway AL, "Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink", Vaccine, 31, pp.2898~2903 (2013)[DOI]
- Hornbrook MC, "Development of an algorithm to identify pregnancy episodes in an integrated health care delivery system", Health Serv Res, 42, pp.908~927 (2007)[DOI]
- Seo GH, "Antithyroid drugs and congenital malformations : a nationwide Korean cohort study", Ann Intern Med, 168, pp.405~413 (2018)[DOI]
- Lee KS, "Association of preterm birth with medications : machine learning analysis using national health insurance data", Arch Gynecol Obstet, 305, pp.1369~1376 (2022)[DOI]
- Choi A, "Association between proton pump inhibitor use during early pregnancy and risk of congenital malformations", JAMA Netw Open, 6, pp.e2250366~ (2023)[DOI]
- Huybrechts KF, "Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy", Pharmacoepidemiol Drug Saf, 28, pp.906~922 (2019)[DOI]
- Andreoli L, "EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and", or antiphospholipid syndrome, 2017, pp.76, 476~485
- Fanouriakis A, "Update οn the diagnosis and management of systemic lupus erythematosus", Ann Rheum Dis, 80, pp.14~25 (2021)[DOI]
- Sammaritano LR, "2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases", Arthritis Care Res(Hoboken), 72, pp.461~488 (2020)[DOI]
- Rajendran A, "The importance of pregnancy planning in lupus pregnancies", Lupus, 30, pp.741~751 (2021)[DOI]
- Seong SC, "Data resource profile : the National Health Information Database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)[DOI]
- Kim HO, "Association between pregnancy outcomes and radioactive iodine treatment after thyroidectomy among women with thyroid cancer", JAMA Intern Med, 180, pp.54~61 (2020)[DOI]
- Joo YB, "Pregnancy rates and perinatal outcomes in women with systemic lupus erythematosus : data from the Korean national health claims database", Clin Rheumatol, 40, pp.2243~2250 (2021)[DOI]
- Noh Y, "Trends and associated maternal characteristics of antidiabetic medication use among pregnant women in South Korea", Sci Rep, 11, pp.4159~ (2021)[DOI]
- Margulis AV, "Algorithms to estimate the beginning of pregnancy in administrative databases", Pharmacoepidemiol Drug Saf, 22, pp.16~24 (2013)[DOI]
- Lee WR, "Recent improvements in medical expense support policies for newborns in South Korea : focusing on the activities of the Korean Society of Neonatology", Perinatology, 28, pp.109~114 (2017)[DOI]
- "Establishment of ultrasonic adequacy evaluation plan" (2018)[URL]
- Koh JH, "Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus", Lupus, 24, pp.210~217 (2015)[DOI]
- Seo MR, "Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia", Lupus, 28, pp.722~730 (2019)[DOI]
- Tani C, "Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study", Rheumatology (Oxford), 60, pp.5610~5619 (2021)[DOI]
- Gohr M, "Improved pregnancy outcomes in systemic lupus erythematosus : a retrospective study of pregnancies from a single centre in Denmark from 2010-2020 compared with the period 1990-2010", Lupus, 31, pp.1202~1210 (2022)[DOI]
- Janardana R, "Maternal and fetal outcomes of lupus pregnancies : a collective effort by Karnataka rheumatologists", Lupus, 29, pp.1397~1403 (2020)[DOI]
- Kroese SJ, "Hydroxychloroquine use in lupus patients during pregnancy is associated with longer pregnancy duration in preterm births", J Immunol Res, 2017, pp.2810202~ (2017)[DOI]
- Kim JW, "Lupus low disease activity state achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus", J Rheumatol, 48, pp.707~716 (2021)[DOI]
- Statistics Korea, "Birth statistics in 2021", Statistics Korea, 1~43 (2022)
- Zhu Y, "Validation of claims-based algorithms to identify non-live birth outcomes", Pharmacoepidemiol Drug Saf, 32, pp.468~474 (2023)[DOI]
